Image-guided stereotactic body radiotherapy for lung tumors using BodyLoc with tomotherapy: clinical implementation and set-up accuracy.

We investigated the use of a BodyLoc immobilization and stereotactic localization device combined with TomoTherapy megavoltage CT (MVCT) in lung stereotactic body radiotherapy (SBRT) to reduce set-up uncertainty and treatment time. Eight patients treated with 3-5 fractions of SBRT were retrospectively analyzed. A BodyLoc localizer was used in both CT simulation for localization and the initial patient treatment set-up. Patients were immobilized with a vacuum cushion on the back and a thermoplastic body cast on the anterior body. Pretreatment MVCT from the TomoTherapy unit was fused with the planning kilovoltage CT (KVCT) before each fraction of treatment to determine interfractional set-up error. The comparison of two MVCTs during a fraction of treatment resulted in the intrafractional uncertainty of the treatment. A total of 224 target isocenter shifts were analyzed to assess these inter- and intrafractional tumor motions. We found that for interfractional shifts, the mean set-up errors and standard deviations were -1.1 +/- 2.8 mm, -2.5 +/- 8.7 mm, and 4.1 +/- 2.6 mm, for lateral, longitudinal, and vertical variation, respectively; the mean setup rotational variation was -0.3 +/- 0.7 degrees; and the maximum motion was 13.5 mm in the longitudinal direction. For intrafractional shifts, the mean set-up errors and standard deviations were -0.1 +/- 0.7 mm, -0.3 +/- 2.0 mm, and 0.5 +/- 1.1 mm for the lateral, longitudinal, and vertical shifts, respectively; the mean rotational variation was 0.1 +/- 0.2 degrees; and the maximum motion was 3.8 mm in the longitudinal direction. There was no correlation among patient characteristics, set-up uncertainties, and isocenter shifts, and the interfractional set-up uncertainties were larger than the intrafractional isocenter shift. The results of this study suggested that image-guided stereotactic body radiotherapy using the BodyLoc immobilization system with TomoTherapy can improve treatment accuracy.

Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma.

PURPOSE: To review a historical cohort of consecutively accrued patients with high-risk neuroblastoma treated with intraoperative radiotherapy (IORT) to determine the therapeutic effect and late complications of this treatment. METHODS AND MATERIALS: Between 1986 and 2002, 31 patients with newly diagnosed high-risk neuroblastoma were treated with IORT as part of multimodality therapy. Their medical records were reviewed to determine the outcome and complications. Kaplan-Meier probability estimates of local control, progression-free survival, and overall survival at 36 months after diagnosis were recorded. RESULTS: Intraoperative radiotherapy to the primary site and associated lymph nodes achieved excellent local control at a median follow-up of 44 months. The 3-year estimate of the local recurrence rate was 15%, less than that of most previously published series. Only 1 of 22 patients who had undergone gross total resection developed recurrence at the primary tumor site. The 3-year estimate of local control, progression-free survival, and overall survival was 85%, 47%, and 60%, respectively. Side effects attributable to either the disease process or multimodality treatment were observed in 7 patients who developed either hypertension or vascular stenosis. These late complications resulted in the death of 2 patients. CONCLUSIONS: Intraoperative radiotherapy at the time of primary resection offers effective local control in patients with high-risk neuroblastoma. Compared with historical controls, IORT achieved comparable control and survival rates while avoiding many side effects associated with external beam radiotherapy in young children. Although complications were observed, additional analysis is needed to determine the relative contributions of the disease process and specific components of the multimodality treatment to these adverse events.

3D inverse treatment planning for the tandem and ovoid applicator in cervical cancer.

PURPOSE: Three-dimensional treatment planning systems and inverse planning optimization for brachytherapy are becoming commercially available. Guidelines for target delineation and dose constrictions have not been established using this new software. In this study we describe a method of target delineation for the tandem and ovoids applicator. We then compare inverse planning dose distributions with the traditional methods of prescribing dose. METHODS AND MATERIALS: Target and organ-at-risk volumes were defined using systematic guidelines on 15 patients treated in our department with high-dose-rate brachytherapy for cervical cancer using tandem and ovoids. High-dose-rate distributions were created according to three different dose optimization protocols: inverse planning simulated annealing (IPSA), point A, and point A with a normalization of 2 cc of the bladder receiving 80% of the dose (bladder-sparing method). An uniform cost function for dose constraints was applied to all IPSA generated plans, and no manual optimization was allowed for any planning method. RESULTS: Guidelines for target and structure-at-risk volumes, as well as dose constraint cost functions, were established. Dose-volume histogram analysis showed that the IPSA algorithm indicated no difference in tumor coverage compared with point A optimization while decreasing dose to the bladder and rectum. The IPSA algorithm provided better target volume coverage compared with bladder-sparing method with equivalent doses to the bladder and rectum. CONCLUSION: This study uses a systematic approach for delineating target and organ-at-risk volumes and a uniform cost function for generating IPSA plans for cervical cancer using tandem and ovoids. Compared with conventional dose prescription methods, IPSA provides a consistent method of optimization that maintains or improves target coverage while decreasing dose to normal structures. Image-guided brachytherapy and inverse planning improve brachytherapy dosimetry.